MiMedx Group, Inc. develops and commercializes regenerative biomaterial products for wound care, burn and surgical applications. Its updates center on placental allografts and related advanced wound care technologies, including AMNIOFIX, CHORIOFIX and G4Derm Plus, as the company adds product configurations, distribution rights and clinical evidence for complex wound management.
Company news also covers operating results for the Wound and Surgical businesses, reimbursement-driven market conditions, cost-reduction actions, investor presentations, conference participation and capital actions such as share repurchase authorization.
MiMedx Group, Inc. (Nasdaq: MDXG) announced first quarter 2024 results with net sales of $85 million, 18% growth year-over-year, GAAP net income of $9 million, adjusted EBITDA of $19 million, and other notable achievements like portfolio expansion and new directors.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.